Detalles de la búsqueda
1.
Improved nationwide survival of sarcoma patients with a network of reference centers.
Ann Oncol
; 35(4): 351-363, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38246351
2.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ann Oncol
; 35(3): 248-266, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38307807
3.
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Ann Oncol
; 34(2): 152-162, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564284
4.
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Ann Oncol
; 34(12): 1152-1164, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797734
5.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ann Oncol
; 34(8): 681-692, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37211045
6.
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol
; 170: 221-228, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36709663
7.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Ann Oncol
; 33(6): 593-601, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35219776
8.
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
Ann Oncol
; 33(3): 276-287, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861371
9.
Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
Gynecol Oncol
; 165(3): 637-641, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35393217
10.
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
Ann Oncol
; 32(8): 1034-1044, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33932507
11.
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol
; 163(3): 465-472, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34642026
12.
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Ann Oncol
; 31(9): 1148-1159, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32569725
13.
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Ann Oncol
; 31(12): 1606-1622, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33004253
14.
The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
Gynecol Oncol
; 157(1): 78-84, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32131977
15.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Ann Oncol
; 30(5): 672-705, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31046081
16.
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
Ann Oncol
; 30(5): 757-765, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30865223
17.
Surgery in reference centers improves survival of sarcoma patients: a nationwide study.
Ann Oncol
; 30(7): 1143-1153, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31081028
18.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Int J Gynecol Cancer
; 2019 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31048403
19.
Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group.
Int J Gynecol Cancer
; 29(4): 691-698, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30772825
20.
Author Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study.
Br J Cancer
; 118(12): 1682, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29808016